systemic%20lupus%20erythematosus%20(pediatric)
SYSTEMIC LUPUS ERYTHEMATOSUS (PEDIATRIC)
Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Childhood-onset SLE has a greater disease severity and earlier disease damage than in adults with SLE.

Systemic Lupus Erythematosus (Pediatric) Drug Information

Drug Information

Indication: Eczema including atopic, infantile & discoid eczemas; prurigo nodulis; psoriasis (excluding widespread pla...

Indication: Eczema including atopic, infantile, discoid & stasis eczema; prurigo; psoriasis; neurodermatoses including...

Indication: Short-term treatment of corticosteroid-responsive resistant dermatoses eg, psoriasis, recalcitrant eczema, lic...

Indication: Symptomatic treatment of allergic dermatoses & other forms of contact dermatitis, insect bites; atopic, ec...

Indication: Reducing disease activity in adult patients w/ active autoantibody +ve SLE receiving standard therapy.

Indication: Relief of inflammatory manifestations of corticosteroid-responsive dermatoses.

Indication: Suppression of skin diseases in which inflammation is a prominent feature.

Indication: Suppression of skin diseases in which inflammation is a prominent feature.

Indication: Relief of inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses (eg, psoriasis, e...

Indication: Acute & chronic rheumatic fever, RA, bronchial asthma, myositis, dermatitis.

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Nov 2020
Antiviral treatment with tenofovir alafenamide fumarate (TAF) during pregnancy in highly viraemic mothers effectively prevents mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with no safety concerns, according to two studies presented during the AASLD 2020 Liver Meeting.